Novo Nordisk Inks $2 Billion Deal for FedLab's GLP-1-Based Long-Acting Triple Agonist UBT251

Mar 24, 2025 20:45 CST Updated 20:45

The United Laboratories

Comprehensive pharmaceutical manufacturer

Novo Nordisk

Insulin Developer and Manufacturer

On March 24, The United LaboratoriesAnnounce,With Novo NordiskNovo Nordisk Enters into Exclusive License Agreement. The United LaboratoriesInvolved in the discussionUBT251 , aGLP-1 Receptor(Glucagon-Like Peptide-1）、GIP Receptor (Glucose-Dependent PromotingA Triple Agonist of Insulin Polypeptide and Glucagon Receptor, in the early stage of clinical development, for the treatment of obesityFat,2 Type diabetes and other diseases. The total transaction amount reached$20 billion。

Source of screenshot: Corporate announcement

According to the exclusive license agreement, Novo Nordisk will obtain global rights (excluding mainland China, Hong Kong Special Administrative Region , MacaoSpecial Administrative Region and Taiwan）Development, Manufacturing and Commercialization UBT251 The Right 。The United LaboratoriesWill be retained UBT251 In mainland China , the rights of the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and the Taiwan Region 。

According to the exclusive license agreement and subject to its terms and conditions, The United Laboratories will haveQualification Collection 2 Billion USD PrePayment and Maximum 18 Potential milestone payments in billions of dollars , Depending on reachingDepending on several development and sales milestones, as well as A tiered sales commission based on the annual net sales in the region may be collected.

UBT251 is a long-acting synthetic peptide triple agonist targeting GLP-1, GIP, and glucagon receptors, which has demonstrated potent activity against all three receptors in preclinical settings.

UBT251 is classified as a Class 1 innovative drug in China, developed by The United Laboratories, and involves multiple indications. To date, UBT251 has been approved for use in China.Type 2 Diabetes Mellitus in Adults, Overweight or Obesity, Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), and Chronic Kidney Disease (CKD)Clinical trials, and approved for use in the United States for adult type 2 diabetes, overweight or obesity, and CKD clinical trials.

The United Laboratories International Holdings Ltd recently launched the Phase 2 trial of UBT251 among overweight or obese populations in China.

Scan the WeChat QR code, add the editor of the Biopharmaceutical Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!

Edition
Authority
Sound
Ming

All articles reproduced in this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reprinted can contact us (cbplib@163.com), and we will immediately delete the content. All articles represent the views of the author, not this site.